Technology area: Biotechnology & Pharmaceuticals
247 pending office actions • 128 clients • 217 examiners • 105 art units • 0 of 247 (0%) have an AI response strategy ready
FOLEY HOAG, LLP (General) has 253 pending office actions in Biotechnology & Pharmaceuticals and 9102 career applications. Its resolved allowance rate is 76.62%, and allowed matters average 3.34 office actions. The profile presents a sizeable active docket and an extensive application record in a specialized technology area.
The resolved allowance rate measures outcomes across the recorded application history, while the action average reflects examination activity associated with allowed matters. The figures therefore support separate evaluation of resolution and prosecution effort. For biotechnology and pharmaceutical practitioners, the data can inform portfolio review and response-resource planning, but it does not predict the result of a particular pending application.
Based on the USPTO statutory response window for each pending office action. 68 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 68 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 4 (2%) |
| §101 + other | 23 (9%) |
| §103 only | 58 (23%) |
| §102 only | 12 (5%) |
| §112 only | 27 (11%) |
| Double-patenting only | 3 (1%) |
| Double-patenting + other | 35 (14%) |
| Multi-statute (no §101) | 82 (33%) |
| No statute on record | 3 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VALENROD, YEVGENY | 4 | 72.5% | +25.1% |
| RONEY, CELESTE A | 3 | 63.0% | +17.4% |
| TIEN, LUCY MINYU | 3 | 59.1% | +36.8% |
| JOHNSON, CHRISTOPHER LINDSAY | 3 | 48.6% | +78.3% |
| HERNANDEZ, JACKSON J | 3 | 50.7% | +39.2% |
| ROZOF, TIMOTHY R | 2 | 72.7% | +23.3% |
| PALENIK, JEFFREY T | 2 | 53.5% | +27.0% |
| FAN, WEIHUA | 2 | 83.3% | +12.7% |
| CHANG, KYUNG SOOK | 2 | 60.5% | +40.8% |
| LEE, CHIHYI NMN | 2 | 33.3% | +61.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19334077 | HYBRID PEPPER VARIETY 'E20S0492' | FAN, WEIHUA | — |
| 19333918 | HYBRID PEPPER VARIETY 'E20S0463' | FAN, WEIHUA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18977008 | VACCINES COMPRISING METHANOBREVIBACTER GOTTSCHALKII | FOLEY, SHANON A | 264d overdue |
| 16964965 | ANTIBODY-DRUG CONJUGATES THAT TARGET DLK1 AND USES THEREOF | PUTTLITZ, KARL J | 219d overdue |
| 18529532 | AIR CONDITIONING SYSTEM WITH MULTIPLE ENERGY STORAGE SUB-SYSTEMS | LAWRENCE JR, FRANK M | 124d overdue |
| 18014580 | INTERLEUKIN 33 (IL-33) INHIBITION FOR TREATMENT OF CANCER, FIBROSIS AND INFLAMMATION | HERNANDEZ, JACKSON J | 91d overdue |
| 18478179 | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES | MCKNIGHT, CIARA A | 89d overdue |
| 16640942 | METHODS FOR MODULATING THE INTERACTION BETWEEN EWS-FLI1 AND BAF COMPLEXES | DENT, ALANA HARRIS | 87d overdue |
| 18283158 | VACCINE ADJUVANT | OH, TAYLOR V | 60d overdue |
| 18269869 | HEPATOCELLULAR CARCINOMA TREATMENTS, PROPHYLACTIC THERAPIES, AND COMPOSITIONS FOR USE THEREWITH | IANNUZO, NATALIE NMN | 50d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014580 | INTERLEUKIN 33 (IL-33) INHIBITION FOR TREATMENT OF CANCER, FIBROSIS AND INFLAMMATION | HERNANDEZ, JACKSON J | 91d overdue |
| 17917233 | MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS | RONEY, CELESTE A | 24d overdue |
| 18562719 | MPLA COMPOSITIONS AND METHODS OF USE | TIEN, LUCY MINYU | 17d overdue |
| 18007822 | METHODS OF TREATING A CORONAVIRUS INFECTION | JOHNSON, CHRISTOPHER LINDSAY | 3d overdue |
| 18285570 | SILICA-BASED FORMULATIONS OF THERAPEUTIC OLIOGPEPTIDES AND PEPTIDOMIMETICS | TIEN, LUCY MINYU | 7d |
| 17482579 | TREATMENT OF ALZHEIMER'S DISEASE (AD) WITH AN ALUMINUM SALT | TIEN, LUCY MINYU | 21d |
| 19170782 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | VALENROD, YEVGENY | 55d |
| 18268688 | DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS | HERNANDEZ, JACKSON J | 56d |
| Art Unit | Apps |
|---|---|
| 1628 | 12 |
| 1625 | 11 |
| 1626 | 9 |
| 1615 | 8 |
| 1663 | 7 |
| 1637 | 7 |
| 1612 | 6 |
| 1624 | 5 |
| 1623 | 5 |
| 3774 | 5 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19567925 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Amazentis SA | VALENROD, YEVGENY | 1628 | DP | Non-Final OA | — | Pending | Mar 16, 2026 |
| 19542047 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY ARTERIAL HYPERTENSION | Inhibikase Therapeutics, Inc. | ROZOF, TIMOTHY R | 1625 | §102§103 | Final Rejection | — | Pending | Feb 17, 2026 |
| 19436348 | COMPOSITIONS COMPRISING AN ACTIVE INGREDIENT MIXTURE COMPRISING SILICON AND BIOTIN AND METHODS OF USE | Nutrition21, LLC | PALENIK, JEFFREY T | 1615 | §102§103DP | Final Rejection | — | Pending | Dec 30, 2025 |
| 19371866 | FORMULATIONS COMPRISING INOSITOL, SILICATES, AND OPTIONALLY AMINO ACIDS WITH IMPROVED SOLUBILITY AND METHODS OF MAKING THE SAME | Nutrition21, LLC | TCHERKASSKAYA, OLGA V | 1615 | §103§112DP | Final Rejection | — | Pending | Oct 28, 2025 |
| 19334077 | HYBRID PEPPER VARIETY 'E20S0492' | Enza Zaden Beheer B.V. | FAN, WEIHUA | 1663 | §112 | Non-Final OA | — | Pending | Sep 19, 2025 |
| 19333918 | HYBRID PEPPER VARIETY 'E20S0463' | Enza Zaden Beheer B.V. | FAN, WEIHUA | 1663 | §112 | Non-Final OA | — | Pending | Sep 19, 2025 |
| 19311619 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Amazentis SA | VALENROD, YEVGENY | 1628 | §103 | Non-Final OA | — | Pending | Aug 27, 2025 |
| 19131469 | A SPINACH PLANT RESISTANT TO DOWNY MILDEW AND A RESISTANCE GENE | Enza Zaden Beheer B.V. | DEVEAU ROSEN, JASON | 1662 | §112 | Final Rejection | — | Pending | May 20, 2025 |
| 19179503 | HYBRID PEPPERS 'E20B.30395' AND 'E20B.30396' | Enza Zaden Beheer B.V. | BYRNES, DAVID R | 1662 | §101§112 | Non-Final OA | — | Pending | Apr 15, 2025 |
| 19173468 | DUAL STRUT POWER TRANSMISSION HOUSING STRUCTURE OF A MARINE PROPULSION SYSTEM | Flux Marine Ltd. | AVILA, STEPHEN P | 3615 | §103 | Non-Final OA | — | Pending | Apr 08, 2025 |
| 19170782 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Amazentis SA | VALENROD, YEVGENY | 1628 | §103 | Non-Final OA | 55d | Pending | Apr 04, 2025 |
| 19095805 | HIDDEN DESKTOP SESSION FOR REMOTE ACCESS | Connectwise, LLC | TANG, KAREN C | 2447 | §103Other | Non-Final OA | — | Pending | Mar 31, 2025 |
| 19080090 | RETRACTABLE MOLD BUILT-IN PRECISION PINS TO LOCATE COMPONENTS DURING LAYUP PROCESS FOR FABRICATION OF WIND TURBINE BLADES | Tpi Technology Inc. | DANIELS, MATTHEW J | 1742 | §103§112 | Non-Final OA | — | Pending | Mar 14, 2025 |
| 19067282 | DELIVERY OF SUSTAINED LOCAL AND SYSTEMIC IMMUNOMODULATION | The Brigham And Women'S Hospital, Inc. | CHANG, KYUNG SOOK | 1613 | §103§112 | Non-Final OA | — | Pending | Feb 28, 2025 |
| 19025640 | HEMOSTASIS VALVE AND DELIVERY SYSTEMS | Bolton Medical, Inc. | SCHERBEL, TODD J | 3771 | §102 | Non-Final OA | — | Pending | Jan 16, 2025 |
| 19008130 | SPEAKER WITH OBLIQUE MOUNTED BASS DRIVER | Lenbrook Industries Limited | GAUTHIER, GERALD | 2692 | §102 | Non-Final OA | — | Pending | Jan 02, 2025 |
| 18878271 | RESISTANCE GENE AND LETTUCE PLANT RESISTANT TO FUSARIUM WILT | Enza Zaden Beheer B.V. | PAGE, BRENT T | 1663 | §101§102§103 | Final Rejection | — | Pending | Dec 23, 2024 |
| 18877765 | COMPOSITIONS AND METHODS FOR TREATING HEARING AND OCULAR DISORDERS | Anida Pharma Inc. | JARRELL, NOBLE E | 1629 | §102§103 | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18978865 | HYBRID TOMATO VARIETIES ‘E15M43062’ AND ‘E16R43164’ | Enza Zaden Beheer B.V. | BOGGS, RUSSELL T | 1663 | §112 | Non-Final OA | — | Pending | Dec 12, 2024 |
| 18977008 | VACCINES COMPRISING METHANOBREVIBACTER GOTTSCHALKII | Arkea Bio Corp. | FOLEY, SHANON A | 1671 | §103§112 | Non-Final OA | 264d overdue | Pending | Dec 11, 2024 |
| 18873070 | NOVEL TREATMENT | University Of Liverpool | HASTINGS, ALISON AZAR | 1627 | §103§112 | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18869024 | LETTUCE PLANT RESISTANT TO DOWNY MILDEW AND RESISTANCE GENE | Enza Zaden Beheer B.V. | WILLIAMS, KEITH RICHARD | 1663 | §103§112 | Final Rejection | — | Pending | Nov 25, 2024 |
| 18956959 | CRYSTALLINE FORMS OF 3-SUBSTITUTED 1,2,4- OXADIAZOLE | Aurigene Discovery Technologies Limited | JACKSON, SHAWQUIA | 1626 | DP | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18947339 | SYSTEM AND METHOD TO RADIALLY CONSTRICT A STENT GRAFT | Bolton Medical, Inc. | RWEGO, KANKINDI | 3771 | §102§103Other | Final Rejection | — | Pending | Nov 14, 2024 |
| 18863566 | IMMUNOBIOTICS FOR PREVENTING BACTERIAL PNEUMONIA AND METHODS OF USING THE SAME | The Regents of the University of Colorado | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103§112 | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18927310 | ANIMAL POSITIONING AND MONITORING SYSTEM FOR MICROSCOPY | Northeastern University | MORALES, JON ERIC C | 3786 | §102 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18913731 | DNA COLLECTION DEVICE | Sapphiros Laboratories LLC | MELHUS, BENJAMIN S | 3791 | §102§112 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18913578 | ARCHITECTURES OF LARGE LANGUAGE MODELS FOR MEDICAL TREATMENT DECISION SUPPORT | Trialmatch.Me, Inc. D/B/A/Trialjectory | ZHU, RICHARD Z | 2654 | §103 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18912145 | TEST PLUG FOR SPRINKLER ADAPTER | Ipex Usa LLC | LU, HAOTIAN | 3753 | §103 | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18907230 | FEATURE PYRAMIDING FOR IN SITU DATA VISUALIZATIONS (AKA DYNAMIC DISPLAY OF MOLECULAR INFORMATION DEPENDENT ON ZOOM LEVEL) | 10X Genomics, Inc. | HUYNH, VAN D | 2665 | §102§103 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18903464 | STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF | Shanghai Hansoh Biomedical Co., Ltd. | BURKETT, DANIEL JOHN | 1624 | §102§112DP | Non-Final OA | — | Pending | Oct 01, 2024 |
| 18897839 | STYLUS DERIVED METRICS TO DETECT CENTRAL AND PERIPHERAL NERVOUS SYSTEM ATTRIBUTES | Linus Health, Inc. | OGLES, MATTHEW ERIC | 3792 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18894797 | HUMAN PLASMA KALLIKREIN INHIBITORS | Biocryst Pharmaceuticals, Inc. | SAEED, KAMAL A | 1626 | DP | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18891617 | CRYSTALLINE SALT FORMS OF BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2 | Stealth BioTherapeutics Inc. | REYNOLDS, FRED H | 1658 | §112DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18886316 | GENOTYPE-AGNOSTIC RESCUE OF CYSTIC FIBROSIS WITH SMALL MOLECULE BICARBONATE CHANNELS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | RONEY, CELESTE A | 1612 | §103DP | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18886318 | GENOTYPE-AGNOSTIC RESCUE OF CYSTIC FIBROSIS WITH SMALL MOLECULE BICARBONATE CHANNELS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | RONEY, CELESTE A | 1612 | §103§112DP | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18885581 | Inter-Frequency Signal Aiding For Tracking Satellite Navigation Signals | The Regents of the University of Colorado | GREGORY, BERNARR E | 3648 | §101§103§112 | Non-Final OA | — | Pending | Sep 14, 2024 |
| 18828513 | PERIODIC EXTENSIONAL FLOW REACTOR | United States Army Research Laboratory | MORENO HERNANDEZ, JERZI H | 1743 | §102§103§112 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18845283 | METHODS OF TREATING CANCER AND OTHER CONDITIONS WITH A MU OPIOID RECEPTOR ANTAGONIST | Glycyx Mor Inc. | LEE, CHIHYI NMN | 1628 | §102§103§112DP | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18827231 | METHODS OF TREATING COGNITIVE IMPAIRMENT | Neurotherapia, Inc. | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §103§112 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18825626 | ULTRA-LOW POWER TEMPERATURE SENSOR DESIGN | Northeastern University | LIN, ERICA S Y | 2849 | §102§103 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18843876 | INTRAORAL MONITOR AND METHODS OF MANUFACTURE | UCHU Biosensors, Inc. | WRIGHT, ALEXANDER SCOTT | 1745 | §102§103§112 | Non-Final OA | — | Pending | Sep 04, 2024 |
| 18842526 | SPINACH PLANT RESISTANT TO DOWNY MILDEW AND NOVEL RESISTANCE GENE | Enza Zaden Beheer B.V. | ORDAZ, CHRISTIAN JOSE | 1663 | §112 | Final Rejection | 26d | Pending | Aug 29, 2024 |
| 18819461 | COMPUTATIONAL SIMULATION PLATFORM FOR PLANNING OF INTERVENTIONAL PROCEDURES | The Board Of Regents Of The University Of Nebraska | TORRES, JOSE | 2664 | §103§112 | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18841884 | COMPOSITIONS COMPRISING AN ACTIVE INGREDIENT MIXTURE COMPRISING SILICON AND BIOTIN AND METHODS OF USE | Nutrition21, LLC | PALENIK, JEFFREY T | 1615 | §102 | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18806984 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | Sensorium Therapeutics, Inc. | RZECZYCKI, PHILLIP MATTHEW | 1625 | §103§112DP | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18799074 | ALKYL-SUBSTITUTED DERIVATIVES OF MESEMBRINE AND MESEMBRENONE AND THERAPEUTIC USES THEREOF | Sensorium Therapeutics, Inc. | BRAUN, MADELINE E | 1624 | §103DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18799037 | THERAPEUTIC ALKALOID COMPOUNDS | Sensorium Therapeutics, Inc. | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18799720 | METHOD FOR PRODUCING A COATED PERFORATED STEEL STRIP | Voestalpine Stahl GmbH | PENNY, TABATHA L | 1712 | §103 | Final Rejection | — | Pending | Aug 09, 2024 |
| 18790836 | EXTENSIBILITY NETWORKING LAYER OF AN INTEGRATION SYSTEM | Connectwise, LLC | NGUYEN, HAO HONG | 2447 | §103 | Final Rejection | 70d | Pending | Jul 31, 2024 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial76.6% of resolved applications prosecuted by Foley Hoag, LLP (General) were allowed, across 9,102 applications in USPTO records.
3.34 office actions per allowed application on average.
247 pending office actions as of October 2026, for 128 clients, before 217 examiners in 105 art units.
